A Single-center, Prospective, Self-controlled, Observational Real-world Study of the Efficacy and Safety of Anti-IL-17A/F Monoclonal Antibody Combined With Non-ablative Dot Laser for the Treatment of Mild to Moderate Hidradenitis Suppurativa
A legfontosabb adatok
- Ki végzi
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Hol
- Hangzhou (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 4. fázis
- Résztvevők
- 50 fő, tervezett
- Kezdés
- 2026. ápr. 1.
- Várható befejezés
- 2027. szept. 30.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- IL-17A/F mAb + NAFL
- A regiszteradat frissítve
- 2026. április 28.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with mild to moderate hidradenitis suppurativa (HS), a long-term skin disease with painful lumps. They get an IL-17A/F antibody plus non-ablative fractional laser treatment.
- Életkor
- 18 years and older
- Nem
- All sexes
- A betegség stádiuma
- Mild to moderate HS, Hurley stage I or II. The disease must be stable, with lesions in at least 1 body area and a total of 3 or more abscesses and inflamed nodules.
- Korábbi kezelés
- People must have taken oral antibiotics for HS for at least 3 months without enough benefit, or could not take them or did not tolerate them, or the disease came back after stopping them. People who used biologics or small molecule targeted drugs before cannot join.
A részvétel fő kizáró okai
- Tunnels under the skin seen on ultrasound at the start
- Other inflammatory diseases, chronic or repeated infections, or a past cancer
- Past drug abuse, suicide attempt or psychiatric disorder
- Corticosteroids taken by mouth or injection in the past 4 weeks, or on the skin in the past 2 weeks
- Pregnant or breastfeeding, or planning a pregnancy during the study
A regiszter feltételei, szó szerint
Mind a 15 feltétel megnézéseKevesebb
Ki vehet részt
- Patients voluntarily participate in the study and sign the informed consent form
- Male or female participants aged ≥ 18 years (at the time of signing the informed consent form)
- Patients with mild to moderate hidradenitis suppurativa: Hurley stage I or II
- Participants have stable disease at screening and baseline, with lesions in ≥ 1 anatomical region and a total abscess and inflammatory nodule (AN) count ≥ 3
- Participants must have intolerance, contraindication, or inadequate response to oral antibiotic treatment for HS for at least 3 months, or have relapsed after stopping such treatment
- Have a basic understanding of the study purpose, the intervention, and possible side effects, and voluntarily sign the informed consent form in accordance with the spirit of the Declaration of Helsinki
- Agree to receive regular treatment, attend follow-up visits, and undergo the required examinations and tests as specified in the clinical study protocol
Ki nem vehet részt
- Prior use of biologics or small molecule targeted agents
- Systemic use of corticosteroids within the past 4 weeks, or topical use within the past 2 weeks
- Known allergy to the study drug or its excipients
- Presence of tunnels on ultrasound at baseline; diagnosed with inflammatory diseases other than HS; history of chronic or recurrent infections; history of malignancy
- History of drug abuse, suicide attempt, or psychiatric disorders
- Any other condition that, in the opinion of the investigator, would make the participant unsuitable for inclusion
- Participated in another clinical trial within the past 3 months
- Pregnant or breastfeeding women, or those planning to become pregnant during the study period
Helyszínek itt: Kína
- 2nd Affiliated Hospital, School of Medicine, Zhejiang University, ChinaHangzhou, KínaContact: Jiaqi ChenToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this clinical trial is to learn if combining an IL-17A/F monoclonal antibody with non-ablative fractional laser therapy works and is safe in patients with mild to moderate hidradenitis suppurativa (HS). The main questions it aims to answer are:
A teljes eredeti leírásKevesebb
Does the combination treatment reduce HS symptoms compared to before treatment? What are the main side effects of this combination treatment? Researchers will compare how participants feel and look after treatment to their own condition before treatment.
Participants will:
Get the combined treatment once every 4 weeks for 16 weeks Give skin and blood samples before the first treatment and at the last treatment visit Have a final check-up 8 weeks after the last treatment
A vizsgálat csoportja
- IL-17A/F mAb + NAFL GroupA vizsgált kezelés
Kezelés: IL-17A/F mAb + NAFL
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. április 28.